Denature News and Research

RSS

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Healthy pre-and post-menopausal Japanese women who took a supplement of SE5-OH containing Natural S-equol, a novel soy germ-based ingredient under development for the management of menopausal symptoms, had measures of reproductive hormones that stayed within normal limits throughout the study.

3 Apr 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.

30 Sep 2009

Nutraceutix receives Chinese patent for probiotic and nutraceutical delivery technology

The Chinese Patent Office has issued Nutraceutix, Inc. patent No. 02823678.5 for BIO-tract. It is the fourth international patent, from many patents pending, that the technology has been awarded recently based on BIO-tract's ability to protect sensitive ingredients such as probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract.

30 Sep 2009